Skip to main navigation
Skip to search
Skip to main content
Xi'an Jiaotong-Liverpool University Home
Home
Profiles
Research units
Research output
Projects
Activities
Search by expertise, name or affiliation
Treg-mediated acquired resistance to immune checkpoint inhibitors
Reem Saleh,
Eyad Elkord
*
*
Corresponding author for this work
Hamad bin Khalifa University
Cancer Research Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
169
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treg-mediated acquired resistance to immune checkpoint inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Immune Checkpoint Inhibitor
100%
Regulatory T Cell
83%
Patient
50%
Malignant Neoplasm
50%
Tumor Microenvironment
50%
Neoplasm
33%
Cancer Types
33%
Immune Response
33%
Immunosuppressive Drug
33%
Combination Therapy
16%
Development
16%
Prognosis
16%
Programmed Cell Death
16%
Upregulation
16%
Disease
16%
Phenotype
16%
Homeostasis
16%
Cell Function
16%
Cytotoxic T-Cell
16%
Immunosuppressive Treatment
16%
Effector Cell
16%
CTLA-4
16%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Malignant Neoplasm
83%
Tumor Microenvironment
50%
Neoplasm
33%
Immunosuppressive Agent
33%
Diseases
16%
CD8 Antigen
16%
Programmed Cell Death
16%
Cytotoxic T Lymphocyte Antigen 4
16%
Prognosis
16%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Regulatory T Cell
62%
Immune Response
25%
Molecule
12%
T Cell
12%
CD8
12%
Programmed Cell Death 1
12%
Development
12%
Phenotype
12%
Upregulation
12%
Cell Function
12%
Lymphocyte
12%
Homeostasis
12%
Immunology and Microbiology
Regulatory T Cell
100%
Immunosuppressive Drug
22%
Immune Response
22%
Cytotoxic T-Cell
11%
Development
11%
Upregulation
11%
Programmed Cell Death 1
11%
Immunosuppression
11%
Effector Cell
11%
CTLA-4
11%
Cell Function
11%
Homeostasis
11%
Molecule
11%
Phenotype
11%